查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1476406

勃起功能障礙藥物的全球市場：分析 - 按藥物類型、給藥途徑、通路、區域、預測（-2030）

Erectile Dysfunction Drugs Market Forecasts to 2030 - Global Analysis By Drug Type (Viagra, Avanafil and Other Drug Types), Route of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

預計2023年全球勃起功能障礙藥物市場規模將達28.3億美元，預測期內複合年成長率為8.8%，2030年將達51.1億美元。

勃起功能障礙 (ED) 藥物是一種旨在治療無法獲得或維持足以進行性交的勃起的藥物。 ED藥物的作用是增加陰莖的血流量，使其在性刺激時更容易勃起。常見的 ED 藥物包括Sildenafil（威而鋼）、他達拉非（犀利士）和伐地那非（艾力達），它們屬於一類稱為5 型磷酸二酯酶(PDE5) 抑制劑的藥物。這些藥物通常是口服給藥，徹底改變了 ED 治療，為數百萬男性提供了可靠有效的解決方案，以改善他們的性能力和生活品質。

根據《臨床流行病學和全球健康雜誌》報道，勃起功能障礙影響全球超過 1.5 億男性，到 2025 年，這一數字預計將增至 3.22 億。根據美國國立衛生美國(NIH) 預測，到 2022 年，勃起功能障礙 (ED) 將成為美國非常常見的疾病，每年影響約 3,000 萬名男性。

意識和接受度不斷提高

勃起功能障礙市場對 ED 藥物的認知和接受度不斷提高，這意味著 ED 作為一種醫療狀況正在被認可和正常化。隨著社會態度的演變以及有關性健康的討論變得更加開放，人們越來越有可能尋求 ED 治療。這種觀念的改變導致人們接受並增加了對 ED 藥物作為合法解決方案的需求。此外，教育宣傳活動和廣告活動在傳播對可用治療方案的認知方面發揮著至關重要的作用，進一步促進了市場成長。

監管障礙

勃起功能障礙藥物市場的監管障礙主要是由於嚴格的核准程序和衛生當局的持續監督。這些障礙包括嚴格的臨床試驗以確定安全性和有效性以及遵守標籤和廣告法規。此外，對潛在副作用以及與其他藥物交互作用的擔憂也增加了監管的複雜性。專利保護和智慧財產權方面的爭議也會延遲市場進入。克服這些監管障礙需要大量的資源和專業知識，這可能會抑制 ED 藥物市場的競爭和創新。

藥物開發創新

勃起功能障礙市場的藥物開發創新為製藥公司和患者提供了充滿希望的機會。隨著研究人員更了解 ED 的根本原因，例如血管問題、神經病變和荷爾蒙失衡，他們可以針對藥物干預的新途徑。與威而鋼和犀利士等現有藥物相比，這項創新可能會帶來更有效、更安全的治療方法，且副作用更少。此外，個人化醫療的突破可能會根據患者的個別特徵進行客製化治療，從而提高療效和患者滿意度。

專利到期

勃起功能障礙藥物市場的專利到期威脅是指威而鋼、犀利士和艾力達等主要藥物即將失去獨佔權。一旦這些專利到期，學名藥可能會進入市場，導致原廠藥品牌的競爭加劇並降低價格。這可能會嚴重影響擁有這些藥物專屬權的製藥公司的收益來源。此外，學名藥通常價格較低，這會促使消費者放棄品牌產品。這種競爭格局為企業在日益激烈的競爭中保持市場佔有率和盈利帶來了挑戰。

COVID-19 的影響：

COVID-19 大流行對勃起功能障礙 (ED) 藥物市場產生了重大影響。由於行動受到限制，醫療保健重點已轉向流行病防範，對 ED 藥物的需求出現了波動。第一次封鎖導致就診次數和處方數量減少，但隨著限制的放鬆和普及遠端醫療的普及，需求增加。由於房屋規定，新婚夫婦和其他親密活動顯著增加，導致與性交相關的活動增加，包括 ED 藥物。經濟不確定性也影響了消費者在 ED 藥物等非必需品上的支出。

威而鋼（Sildenafil西地那非）細分市場預計將在預測期內成為最大的細分市場

威而鋼（Sildenafil）細分市場在 ED 藥物市場的成長可歸因於幾個因素。威而鋼是 ED 治療領域的先驅，在消費者中建立了強大的品牌影響力和信任。威而鋼治療 ED 的功效已得到證實，並被醫生和患者廣泛採用。Sildenafil學名藥學名藥的上市使其變得更加實惠和容易獲得，進一步推動了市場成長。此外，持續的研究和開發工作正在創造創新的配方和交付方法，擴大市場基礎。此外，人們對 ED 認知的提高和尋求治療的非個人化正在促進整個 ED 藥物市場的擴張，其中威而鋼是主導藥物。

預計外用藥物領域在預測期內複合年成長率最高

外用藥物領域的成長歸因於外用製劑提供的便利性和自由裁量權，這吸引了尋求非侵入性治療選擇的消費者。配方技術的進步提高了外用藥物的功效和吸收率，提高了其有效性。患者和醫療保健提供者對局部治療的認知和接受程度不斷提高正在推動市場需求。此外，對全身性副作用較少的局部治療的偏好鼓勵了外用藥物的採用，從而促進了這一領域的持續擴展。

比最大的地區

由於人們對 ED 認知的不斷提高和治療選擇的增多，北美地區的勃起功能障礙藥物市場正在顯著成長。醫療技術的進步促進了更有效、更安全的 ED 藥物的開發，增加了消費者的信任和支持。此外，北美人口老化，壓力和久坐生活方式等生活方式因素也導致ED患者增加，增加了治療需求。該地區強大的醫療基礎設施和優惠的報銷政策有助於輕鬆獲得急診藥物，進一步推動市場成長。

複合年成長率最高的地區：

由於多種因素，亞太地區正在經歷顯著的快速成長。主要促進因素包括性健康意識的提高、文明病盛行率的上升以及醫療服務的普及。此外，更公開地討論性健康的文化轉變正在減少恥辱並鼓勵個人尋求治療。此外，創新治療方案的可用性正在推動市場成長。亞太地區人口眾多，醫療基礎設施發達，為勃起功能障礙藥物市場的進一步擴張提供了重大機會。

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球勃起功能障礙藥物市場：依藥物類型

  • 威而鋼（Sildenafil）
  • 阿伐那非（Stendra/Spedra）
  • 犀利士（他達拉非）
  • Helva（碳酸洛地那非）
  • 艾力達/Staxyn（伐地那非）
  • Mbix（米洛地那非）
  • 維塔羅斯（Alprostadil）
  • Zydena（Udenafil）
  • 其他藥物種類

第6章全球勃起功能障礙治療藥物市場：依給藥途徑

  • 口腔醫學
  • 外用藥
  • 注射

第7章全球勃起功能障礙治療藥物市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第8章全球勃起功能障礙治療藥物市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司概況

  • Abbott Laboratories
  • Allergan plc
  • Apricus Biosciences, Inc.
  • Bayer AG
  • Cristalia Produtos Quimicos Farmaceuticos Ltda.
  • Dong-A Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Futura Medical plc
  • Ion Channel Innovations, LLC
  • Johnson & Johnson
  • Meda Pharmaceuticals Inc.
  • Metuchen Pharmaceuticals, LLC
  • Pfizer Inc.
  • Regent Pacific Group Limited
  • Sandoz International GmbH
  • Sinil Pharmaceutical Co., Ltd.
  • SK Chemicals Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS, Inc.
Product Code: SMRC25952

According to Stratistics MRC, the Global Erectile Dysfunction Drugs Market is accounted for $2.83 billion in 2023 and is expected to reach $5.11 billion by 2030 growing at a CAGR of 8.8% during the forecast period. Erectile dysfunction (ED) drugs are medications designed to treat the inability to achieve or maintain an erection sufficient for sexual intercourse. They work by increasing blood flow to the penis, facilitating an erection when sexually stimulated. Common ED drugs include sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra), which belong to a class of medications called phosphodiesterase type 5 (PDE5) inhibitors. These drugs are typically taken orally and have revolutionized the treatment of ED, offering millions of men a reliable and effective solution to enhance their sexual performance and quality of life.

According to the Clinical Epidemiology and Global Health Journal, Erectile Dysfunction affects more than 150 million men globally, and by 2025, that number is predicted to rise to 322 million. According to the National Institutes of Health (NIH), in 2022, erectile dysfunction (ED) is very common condition in U.S. It affects about 30 million men in the U.S. every year.

Market Dynamics:

Driver:

Growing awareness and acceptance

The growing awareness and acceptance of ED drugs in the erectile dysfunction market signifies the increasing recognition and normalization of ED as a medical condition. As societal attitudes evolve and conversations around sexual health become more open, individuals are more likely to seek treatment for ED. This shift in perception leads to greater acceptance of ED drugs as legitimate solutions, boosting their demand. Additionally, education campaigns and advertising efforts play a crucial role in spreading awareness about available treatment options, further fueling market growth.

Restraint:

Regulatory hurdles

Regulatory hurdles in the erectile dysfunction drug market primarily stem from stringent approval processes and ongoing monitoring by health authorities. These hurdles include rigorous clinical trials to establish safety and efficacy, as well as compliance with labeling and advertising regulations. Additionally, concerns over potential side effects and interactions with other medications contribute to the regulatory complexity. Market entry may also be delayed by patent protections and intellectual property disputes. Navigating these regulatory hurdles demands substantial resources and expertise, which can restrain competition and innovation in the ED drug market.

Opportunity:

Innovation in drug development

The innovation in drug development within the erectile dysfunction market presents a promising opportunity for both pharmaceutical companies and patients. With advancements in understanding the underlying causes of ED, such as vascular issues, neurological disorders, and hormonal imbalances, researchers can target novel pathways for drug interventions. This innovation could lead to more effective and safer treatment options, potentially with fewer side effects compared to current medications like Viagra and Cialis. Furthermore, breakthroughs in personalized medicine may enable tailored treatments based on individual patient characteristics, enhancing efficacy and patient satisfaction.

Threat:

Patent expiry

The patent expiry threat in the Erectile Dysfunction drugs market refers to the looming loss of exclusivity for major medications like Viagra, Cialis, and Levitra. As these patents expire, generic versions can enter the market, leading to intense competition and price erosion for the original brands. This could significantly impact revenue streams for pharmaceutical companies that have held exclusive rights to these drugs. Moreover, generic alternatives often come at lower prices, enticing consumers away from branded products. This scenario poses a challenge for companies to maintain market share and profitability in the face of increased competition.

Covid-19 Impact:

The COVID-19 pandemic had a significant impact on the erectile dysfunction (ED) drug market. With restrictions on movement and healthcare priorities shifting towards managing the pandemic, the demand for ED drugs saw fluctuations. While initial lockdowns led to a decrease in doctor visits and prescriptions, there was a subsequent rise in demand as restrictions eased and telemedicine became more prevalent. Due to house restrictions, there was a substantial growth of intimate activities among newlywed couples and others, which consequently led to growth of several things related to intercourse including ED drugs. Economic uncertainties also influenced consumer spending on non-essential medications like ED drugs.

The viagra (sildenafil citrate) segment is expected to be the largest during the forecast period

The growth of the Viagra (Sildenafil Citrate) segment in the ED drug market can be attributed to several factors. Viagra was one of the pioneering drugs in ED treatment, establishing a strong brand presence and trust among consumers. Its efficacy in treating ED is well-established, leading to widespread adoption by physicians and patients alike. The availability of generic versions of Sildenafil Citrate has increased affordability and accessibility, further fueling market growth. Moreover, continuous research and development efforts have resulted in innovative formulations and delivery methods, expanding the market reach. Furthermore, increasing awareness about ED and the destigmatization of seeking treatment have contributed to the overall expansion of the ED drug market, with Viagra leading the charge.

The topical medications segment is expected to have the highest CAGR during the forecast period

The growth in the topical medication segment can be attributed to the convenience and discretion offered by topical formulations, appealing to consumers seeking non-invasive treatment options. Advancements in formulation technology have improved the efficacy and absorption rates of topical medications, enhancing their effectiveness. The growing awareness and acceptance of topical treatments among both patients and healthcare providers have fuelled market demand. Additionally, the preference for localized treatment with fewer systemic side effects has bolstered the adoption of topical medications, contributing to the segment's sustained expansion.

Region with largest share:

The North American region has experienced significant growth in the erectile dysfunction drug market due to increasing awareness about ED and its growing treatment options. Advancements in medical technology have led to the development of more effective and safer ED drugs, boosting consumer confidence and uptake. Additionally, the aging population in North America, coupled with lifestyle factors such as stress and sedentary habits, has contributed to the rise in ED cases, thus driving the demand for treatment. Robust healthcare infrastructure and favourable reimbursement policies in the region have facilitated access to ED drugs, further fuelling market growth.

Region with highest CAGR:

The Asia-Pacific region has witnessed a notable surge due to several factors. Increasing awareness about sexual health, the rising incidence of lifestyle-related disorders, and expanding access to healthcare services are key drivers. Furthermore, cultural shifts towards more open discussions about sexual health have reduced stigma, encouraging individuals to seek treatment. Furthermore, the availability of innovative treatment options has fuelled market growth. With a large population base and improving healthcare infrastructure, the Asia-Pacific region presents significant opportunities for further expansion in the erectile dysfunction drug market.

Key players in the market

Some of the key players in Erectile Dysfunction Drugs market include Abbott Laboratories, Allergan plc, Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co., Ltd., Eli Lilly and Company, Endo International plc, Futura Medical plc, Ion Channel Innovations, LLC, Johnson & Johnson, Meda Pharmaceuticals Inc., Metuchen Pharmaceuticals, LLC, Pfizer Inc., Regent Pacific Group Limited, Sandoz International GmbH, Sinil Pharmaceutical Co., Ltd., SK Chemicals Co., Ltd., Teva Pharmaceutical Industries Ltd. and VIVUS, Inc.

Key Developments:

In March 2024, Johnson & Johnson's JNJ wholly-owned subsidiary, Johnson & Johnson MedTech, recently announced its partnership with Nvidia to accelerate secure, real-time analysis of surgical data using artificial intelligence (AI). The two businesses collaborated to enable more global availability of AI algorithms and real-time analytical access. Their goal is to have an impact on surgical decision-making, teamwork, and education in all linked operating rooms (ORs).

In January 2024, Glenmark said it has partnered with Pfizer to launch abrocitinib in India used for treatment of moderate-to-severe atopic dermatitis (AD). Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO. Developed by Pfizer, abrocitinib has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO).

Drug Types Covered:

  • Viagra (Sildenafil Citrate)
  • Avanafil (Stendra/Spedra)
  • Cialis (Tadalafil)
  • Helleva (Lodenafil Carbonate)
  • Levitra/Staxyn (Vardenafil)
  • Mvix (Mirodenafil)
  • Vitaros (Alprostadil)
  • Zydena (Udenafil)
  • Other Drug Types

Route of Administrations Covered:

  • Oral Medications
  • Topical Medications
  • Injections

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Erectile Dysfunction Drugs Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Viagra (Sildenafil Citrate)
  • 5.3 Avanafil (Stendra/Spedra)
  • 5.4 Cialis (Tadalafil)
  • 5.5 Helleva (Lodenafil Carbonate)
  • 5.6 Levitra/Staxyn (Vardenafil)
  • 5.7 Mvix (Mirodenafil)
  • 5.8 Vitaros (Alprostadil)
  • 5.9 Zydena (Udenafil)
  • 5.10 Other Drug Types

6 Global Erectile Dysfunction Drugs Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral Medications
  • 6.3 Topical Medications
  • 6.4 Injections

7 Global Erectile Dysfunction Drugs Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Online Pharmacies
  • 7.4 Retail Pharmacies

8 Global Erectile Dysfunction Drugs Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott Laboratories
  • 10.2 Allergan plc
  • 10.3 Apricus Biosciences, Inc.
  • 10.4 Bayer AG
  • 10.5 Cristalia Produtos Quimicos Farmaceuticos Ltda.
  • 10.6 Dong-A Pharmaceutical Co., Ltd.
  • 10.7 Eli Lilly and Company
  • 10.8 Endo International plc
  • 10.9 Futura Medical plc
  • 10.10 Ion Channel Innovations, LLC
  • 10.11 Johnson & Johnson
  • 10.12 Meda Pharmaceuticals Inc.
  • 10.13 Metuchen Pharmaceuticals, LLC
  • 10.14 Pfizer Inc.
  • 10.15 Regent Pacific Group Limited
  • 10.16 Sandoz International GmbH
  • 10.17 Sinil Pharmaceutical Co., Ltd.
  • 10.18 SK Chemicals Co., Ltd.
  • 10.19 Teva Pharmaceutical Industries Ltd.
  • 10.20 VIVUS, Inc.

List of Tables

  • Table 1 Global Erectile Dysfunction Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 3 Global Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
  • Table 4 Global Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
  • Table 5 Global Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
  • Table 6 Global Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
  • Table 7 Global Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
  • Table 8 Global Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
  • Table 9 Global Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
  • Table 10 Global Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
  • Table 11 Global Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 12 Global Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 13 Global Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
  • Table 14 Global Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
  • Table 15 Global Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
  • Table 16 Global Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 17 Global Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 18 Global Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 19 Global Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 20 North America Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 22 North America Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
  • Table 23 North America Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
  • Table 24 North America Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
  • Table 25 North America Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
  • Table 26 North America Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
  • Table 27 North America Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
  • Table 28 North America Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
  • Table 29 North America Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
  • Table 30 North America Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 31 North America Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 32 North America Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
  • Table 33 North America Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
  • Table 34 North America Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
  • Table 35 North America Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 36 North America Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 37 North America Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 38 North America Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 39 Europe Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 41 Europe Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
  • Table 42 Europe Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
  • Table 43 Europe Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
  • Table 44 Europe Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
  • Table 45 Europe Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
  • Table 46 Europe Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
  • Table 47 Europe Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
  • Table 48 Europe Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
  • Table 49 Europe Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 50 Europe Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 51 Europe Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
  • Table 52 Europe Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
  • Table 53 Europe Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
  • Table 54 Europe Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 55 Europe Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 56 Europe Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 57 Europe Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 58 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 60 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
  • Table 61 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
  • Table 62 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
  • Table 63 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
  • Table 64 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
  • Table 65 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
  • Table 66 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
  • Table 67 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
  • Table 68 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 69 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 70 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
  • Table 71 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
  • Table 72 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
  • Table 73 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 74 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 75 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 76 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 77 South America Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 79 South America Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
  • Table 80 South America Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
  • Table 81 South America Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
  • Table 82 South America Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
  • Table 83 South America Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
  • Table 84 South America Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
  • Table 85 South America Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
  • Table 86 South America Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
  • Table 87 South America Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 88 South America Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 89 South America Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
  • Table 90 South America Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
  • Table 91 South America Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
  • Table 92 South America Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 93 South America Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 94 South America Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 95 South America Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 96 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 98 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
  • Table 99 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
  • Table 100 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
  • Table 101 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
  • Table 102 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
  • Table 103 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
  • Table 104 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
  • Table 105 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
  • Table 106 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 107 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 108 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
  • Table 109 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
  • Table 110 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
  • Table 111 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 112 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 113 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 114 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)